Pharmacological antibodies targeting PD-1 or its ligand PD-L1 can alleviate the inhibition of antitumor T cells, leading to an immune attack on the tumor (Pardoll, 2012) PD-1/PD-L1 therapy could overcome the immunosuppression status of tumor infiltrated T cell. This evidence concerns the gene CD274 and neoplasm.